Related Experiment Videos
[Major psychiatric side effects of interferon alpha-2b]
M Heeringa1, P Honkoop, R A de Man
1Stichting Landelijke Registratie en Evaluatie Bijwerkingen (LAREB). MH's-Hertogenbosch.
Nederlands Tijdschrift Voor Geneeskunde
|October 9, 1998
Summary
Serious psychiatric symptoms, including depression and psychosis, were reported in six patients using interferon alpha-2b for chronic hepatitis. Early recognition and treatment of these adverse drug reactions are crucial for patient outcomes.
Area of Science:
- Pharmacovigilance
- Hepatology
- Psychiatry
Background:
- Interferon alpha-2b is a treatment for chronic hepatitis B or C.
- Serious psychiatric symptoms have been reported with its use.
Observation:
- Six cases of psychiatric symptoms were reported to the Netherlands Pharmacovigilance Foundation Lareb and the Drug Safety Unit in 1997.
- Patients included three men and three women, with two having prior psychiatric history.
Findings:
- Depression or psychosis developed 12-24 weeks after starting subcutaneous interferon alpha-2b (3-10 million IU/week).
- Four patients recovered after medication cessation; one case outcome was unknown, and one patient died by suicide.
Implications:
- Awareness of these psychiatric adverse drug reactions is essential for healthcare providers.
- Timely recognition and management of symptoms can improve patient prognosis.
- This highlights the importance of monitoring psychiatric side effects during interferon therapy.